Teva Pharmaceutical Industries (NYSE:TEVA) Insider Mark Sabag Sells 46,000 Shares of Company Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) insider Mark Sabag sold 46,000 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $41.93, for a total value of $1,928,780.00. Following the sale, the insider directly owned 80,760 shares of the company’s stock, valued at approximately $3,386,266.80. This trade represents a 36.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Teva Pharmaceutical Industries Stock Up 1.8%

NYSE:TEVA opened at $42.52 on Friday. Teva Pharmaceutical Industries Ltd. has a one year low of $23.61 and a one year high of $43.34. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67. The firm’s 50 day simple moving average is $39.49 and its 200 day simple moving average is $34.79. The company has a market cap of $49.55 billion, a PE ratio of 98.88, a P/E/G ratio of 3.77 and a beta of 0.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The firm had revenue of $4.39 billion during the quarter, compared to analyst estimates of $4.23 billion. During the same quarter last year, the business earned $0.78 earnings per share. The company’s quarterly revenue was down 1.9% on a year-over-year basis. On average, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current year.

Analyst Upgrades and Downgrades

TEVA has been the topic of several recent analyst reports. TD Cowen upped their price target on Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the company a “buy” rating in a research note on Wednesday. HC Wainwright began coverage on Teva Pharmaceutical Industries in a report on Monday, November 2nd. They issued a “buy” rating and a $52.00 price target on the stock. Oppenheimer increased their price objective on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, October 9th. Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday. Finally, Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the stock an “overweight” rating in a research note on Thursday, October 15th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and an average price target of $47.23.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva’s third-quarter earnings beat estimates, and the company raised its 2026 revenue and product-sales outlook, citing strong branded-drug sales. Revenue was slightly lower year over year, but the results and upgraded outlook were encouraging. Article: Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
• Positive Sentiment: A report highlighted 33% sales growth last quarter across Teva’s three key branded medicines, alongside improved margins and net-debt reduction—factors that could strengthen earnings and the balance sheet. Article: Teva’s 3 Key Branded Drugs Grew Sales 33% Last Quarter
• Positive Sentiment: Leerink Partners raised its price target to $52 from $45 and maintained an “outperform” rating, signaling greater analyst confidence in potential upside. Article: Leerink Partners Raises Teva Price Target
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating with a $52 target and projected 2027 EPS of $3.03, well above its 2026 estimate of $1.94. Teva analyst estimates
• Negative Sentiment: Insider Mark Sabag sold 46,000 shares for about $1.93 million, reducing his direct holdings by 36.29%. Insider sales can weigh on sentiment, though they do not necessarily indicate a change in the company’s outlook. SEC insider transaction filing

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of large investors have recently bought and sold shares of TEVA. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 2.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company’s stock worth $1,384,216,000 after purchasing an additional 1,004,941 shares in the last quarter. WCM Investment Management LLC lifted its holdings in Teva Pharmaceutical Industries by 191.4% during the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock valued at $1,157,264,000 after purchasing an additional 26,813,522 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Teva Pharmaceutical Industries by 5.8% during the 2nd quarter. Wellington Management Group LLP now owns 7,671,157 shares of the company’s stock worth $259,899,000 after purchasing an additional 419,329 shares during the last quarter. Janus Henderson Group PLC lifted its position in Teva Pharmaceutical Industries by 1.5% in the first quarter. Janus Henderson Group PLC now owns 4,816,657 shares of the company’s stock valued at $145,076,000 after buying an additional 72,880 shares during the last quarter. Finally, Bessemer Group Inc. increased its holdings in Teva Pharmaceutical Industries by 1.6% during the 1st quarter. Bessemer Group Inc. now owns 4,350,483 shares of the company’s stock worth $131,036,000 after purchasing an additional 70,058 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas.

Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

Teva is headquartered in Tel Aviv, Israel.